<DOC>
	<DOCNO>NCT00988247</DOCNO>
	<brief_summary>Subjects perennial allergic rhinitis randomize 320 mcg beclomethasone dipropionate ( BDP ) use hydrofluoroalkane ( HFA ) propellant placebo nasal aerosol . The subject follow safety efficacy period 30 52 week . BDP HFA steroid currently FDA approve treatment asthma . BDP-HFA safe effective `` dry '' nasal aerosol may prefer patient .</brief_summary>
	<brief_title>Long Term Safety Efficacy Trial Beclomethasone Dipropionate - Hydrofluoroalkane ( BDP-HFA ) 320 Mcg Allergic Rhinitis</brief_title>
	<detailed_description />
	<mesh_term>Rhinitis , Allergic</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Rhinitis , Allergic , Perennial</mesh_term>
	<mesh_term>Beclomethasone</mesh_term>
	<criteria>Male female subject , 12 year age old Screening Visit ( SV ) General good health , free concomitant condition treatment could interfere study conduct , influence interpretation study observations/results , put subject increase risk study A history PAR relevant perennial allergen minimum two year immediately precede study Screening Visit ( SV ) . The PAR must sufficient severity require treatment ( either continuous intermittent ) past , investigator 's judgment expect require treatment throughout entire study A demonstrated sensitivity least one allergen know induce PAR standard skin prick test . A positive test define wheal diameter least 3 mm large diluent control wheal skin prick test . Documentation positive result 12 month prior Screening Visit ( SV ) acceptable Other criterion apply History physical finding nasal pathology , include nasal polyp clinically significant respiratory tract malformation , recent nasal biopsy , nasal trauma , include nasal piercing , surgery atrophic rhinitis rhinitis medicamentosa ( within last 60 day prior Screening Visit [ SV ] ) Participation investigational drug study within 30 day precede Screening Visit ( SV ) plan participation another investigational drug study time study History respiratory infection disorder ( include , limited bronchitis , pneumonia , chronic sinusitis , influenza within 14 day precede Screening Visit ( SV ) development respiratory infection RunIn Period Active asthma require treatment inhale systemic corticosteroid and/or routine use Î²agonists controller drug ( e.g. , theophylline , leukotriene antagonist ) . History intermittent use ( less equal 3 us per week ) inhale short acting betaagonists prior Screening Visit ( SV ) acceptable . Other criterion apply Randomization Criteria Subject continue general good health , meet selection criterion Subject minimum subjectreported reflective TNSS average 5 ( possible 12 ) last 7 day RunIn Period The subjectreported score rhinorrhea nasal congestion must average 2 great last 7 day RunIn Period Each subject must adequately complete electronic AR Assessment Diary ( failure define miss diary entry 2 calendar day last 7 day RunIn Period ) Other criterion apply</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>Rhinitis , Allergic , Perennial</keyword>
	<keyword>BDP-HFA</keyword>
	<keyword>Hay fever</keyword>
	<keyword>Allergic rhinitis</keyword>
</DOC>